English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsNovartis india

    Novartis India

    Jump to
    • Novartis India Standalone June 2025 Net Sales at Rs 87.55 crore, down 5.14% Y-o-Y

      Novartis India Standalone June 2025 Net Sales at Rs 87.55 crore, down 5.14% Y-o-Y

    • Stocks to Watch Today: Indiqube Spaces, GNG Electronics, Dilip Buildcon, GMR Airports, Ask Automotive, GE Vernova, IGI India, L&T in focus on 30 July

      Stocks to Watch Today: Indiqube Spaces, GNG Electronics, Dilip Buildcon, GMR Airports, Ask Automotive, GE Vernova, IGI India, L&T in focus on 30 July

      Stocks to Watch, 30 July: Stocks like Indiqube Spaces, GNG Electronics, Dilip Buildcon, GMR Airports, Ask Automotive, GE Vernova T&D India, International Gemmological Institute India, Bank of India, and Larsen & Toubro will be in focus on July 30.

    • Novartis India Standalone December 2024 Net Sales at Rs 93.00 crore, up 10.01% Y-o-Y

      Novartis India Standalone December 2024 Net Sales at Rs 93.00 crore, up 10.01% Y-o-Y

    • Novartis India Standalone September 2024 Net Sales at Rs 87.10 crore, up 10.59% Y-o-Y

      Novartis India Standalone September 2024 Net Sales at Rs 87.10 crore, up 10.59% Y-o-Y

    • Novartis India Standalone June 2024 Net Sales at Rs 92.29 crore, up 1.87% Y-o-Y

      Novartis India Standalone June 2024 Net Sales at Rs 92.29 crore, up 1.87% Y-o-Y

    • Novartis India Standalone March 2024 Net Sales at Rs 81.17 crore, up 6.62% Y-o-Y

      Novartis India Standalone March 2024 Net Sales at Rs 81.17 crore, up 6.62% Y-o-Y

    • Novartis explores potential transfer of listed business ownership in India

      Novartis explores potential transfer of listed business ownership in India

      Regarding the strategic review of Novartis's listed entity in India, Narasimhan clarified that it was not prompted by any pricing policies within the country

    • Dr Reddy's scales 52-week high on buzz over plans to acquire Novartis' India arm

      Dr Reddy's scales 52-week high on buzz over plans to acquire Novartis' India arm

      The management of Dr Reddy's has also repeatedly expressed their interest in acquiring a domestic-focused portfolio.

    • Novartis AG announces strategic review of Novartis India

      Novartis AG announces strategic review of Novartis India

      Novartis India, a listed entiry, is set to undergo an assessment encompassing various aspects, including its parent Novartis AG's 70.68 percent shareholding.

    • Novartis India Standalone December 2023 Net Sales at Rs 84.54 crore, up 5.45% Y-o-Y

      Novartis India Standalone December 2023 Net Sales at Rs 84.54 crore, up 5.45% Y-o-Y

    • Novartis India Standalone September 2023 Net Sales at Rs 78.76 crore, down 22.42% Y-o-Y

      Novartis India Standalone September 2023 Net Sales at Rs 78.76 crore, down 22.42% Y-o-Y

    • Novartis India falls 3% on kidney transplant drug shortage

      Novartis India falls 3% on kidney transplant drug shortage

      The company said it is putting its best efforts to mitigate the supply issue on a sustainable basis.

    • Novartis India facing shortage of drug ‘Simulect’ used on kidney transplant patients

      Novartis India facing shortage of drug ‘Simulect’ used on kidney transplant patients

      Simulect is an intravenous prescription drug that is used on transplant patients to ensure the body does not reject the new organ

    • Novartis India Standalone June 2023 Net Sales at Rs 90.60 crore, down 25.07% Y-o-Y

      Novartis India Standalone June 2023 Net Sales at Rs 90.60 crore, down 25.07% Y-o-Y

    • Fit to Lead | Novartis India’s Amitabh Dube: ‘Focus keeps you on the right track, discipline helps you to be consistent’

      Fit to Lead | Novartis India’s Amitabh Dube: ‘Focus keeps you on the right track, discipline helps you to be consistent’

      Challenge for 2024: The Novartis India country president and MD will prioritise personal health and wellness. And embrace FOMO, making peace with the fact that one can't always be in the know.

    • Novartis India Standalone March 2023 Net Sales at Rs 76.13 crore, down 22.57% Y-o-Y

      Novartis India Standalone March 2023 Net Sales at Rs 76.13 crore, down 22.57% Y-o-Y

    • Novartis India Standalone December 2022 Net Sales at Rs 80.17 crore, down 18.99% Y-o-Y

      Novartis India Standalone December 2022 Net Sales at Rs 80.17 crore, down 18.99% Y-o-Y

    • Novartis India Standalone December 2022 Net Sales at Rs 80.17 crore, down 18.99% Y-o-Y

      Novartis India Standalone December 2022 Net Sales at Rs 80.17 crore, down 18.99% Y-o-Y

    • Cancer therapy shifting from patient-fitting treatment to treatment-fitting patient model: Novartis India MD

      Cancer therapy shifting from patient-fitting treatment to treatment-fitting patient model: Novartis India MD

      The oncology market in India is estimated to grow by $734.18 million in 2025, growing at a CAGR of over 13 percent. With progress in faster and less expensive gene sequencing, precision medicine is starting to be used more often, most notably in the treatment of lung cancer, says Amitabh Dube.

    • Novartis India Standalone September 2022 Net Sales at Rs 101.52 crore, down 2.83% Y-o-Y

      Novartis India Standalone September 2022 Net Sales at Rs 101.52 crore, down 2.83% Y-o-Y

    • Novartis India Standalone September 2022 Net Sales at Rs 101.52 crore, down 2.83% Y-o-Y

      Novartis India Standalone September 2022 Net Sales at Rs 101.52 crore, down 2.83% Y-o-Y

    • Novartis India Standalone March 2022 Net Sales at Rs 98.32 crore, down 0.98% Y-o-Y

      Novartis India Standalone March 2022 Net Sales at Rs 98.32 crore, down 0.98% Y-o-Y

    • Novartis India transfers sales and distribution to Dr Reddy’s Labs, to axe 400 employees

      Novartis India transfers sales and distribution to Dr Reddy’s Labs, to axe 400 employees

      Interestingly, Novartis which hired over 1,600 employees across divisions in India since January 2020 says it is planning to continue the hiring programme in 2022.

    • Novartis India Standalone December 2021 Net Sales at Rs 98.96 crore, up 5.53% Y-o-Y

      Novartis India Standalone December 2021 Net Sales at Rs 98.96 crore, up 5.53% Y-o-Y

    • Novartis India Standalone June 2021 Net Sales at Rs 98.11 crore, up 6.11% Y-o-Y

      Novartis India Standalone June 2021 Net Sales at Rs 98.11 crore, up 6.11% Y-o-Y

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347